416 related articles for article (PubMed ID: 25361007)
1. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.
Oikonomou E; Koustas E; Goulielmaki M; Pintzas A
Oncotarget; 2014 Dec; 5(23):11752-77. PubMed ID: 25361007
[TBL] [Abstract][Full Text] [Related]
2. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Zhao Y; Yu H; Ida CM; Halling KC; Kipp BR; Geiersbach K; Rumilla KM; Gupta S; Lin MT; Zheng G
JAMA Netw Open; 2021 Jan; 4(1):e2035479. PubMed ID: 33507258
[TBL] [Abstract][Full Text] [Related]
3. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
4. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
5. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
Mochizuki H; Breen M
Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features.
Harada K; Hiraoka S; Kato J; Horii J; Fujita H; Sakaguchi K; Shiratori Y
Br J Cancer; 2007 Nov; 97(10):1425-31. PubMed ID: 17923875
[TBL] [Abstract][Full Text] [Related]
7. A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis.
Joyce T; Oikonomou E; Kosmidou V; Makrodouli E; Bantounas I; Avlonitis S; Zografos G; Pintzas A
Curr Cancer Drug Targets; 2012 Sep; 12(7):873-98. PubMed ID: 22515520
[TBL] [Abstract][Full Text] [Related]
8. New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients.
Ruffinelli JC; Santos Vivas C; Sanz-Pamplona R; Moreno V
Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):65-79. PubMed ID: 32946312
[TBL] [Abstract][Full Text] [Related]
9. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
10. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
11. Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers.
Noda H; Kato Y; Yoshikawa H; Arai M; Togashi K; Nagai H; Konishi F; Miki Y
J Exp Clin Cancer Res; 2006 Jun; 25(2):235-42. PubMed ID: 16918136
[TBL] [Abstract][Full Text] [Related]
12. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.
Makrodouli E; Oikonomou E; Koc M; Andera L; Sasazuki T; Shirasawa S; Pintzas A
Mol Cancer; 2011 Sep; 10():118. PubMed ID: 21943101
[TBL] [Abstract][Full Text] [Related]
13. Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.
Post JB; Roodhart JML; Snippert HJG
Trends Cancer; 2020 Feb; 6(2):111-129. PubMed ID: 32061302
[TBL] [Abstract][Full Text] [Related]
14. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
Platz A; Egyhazi S; Ringborg U; Hansson J
Mol Oncol; 2008 Apr; 1(4):395-405. PubMed ID: 19383313
[TBL] [Abstract][Full Text] [Related]
15. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
Sclafani F; Gullo G; Sheahan K; Crown J
Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
[TBL] [Abstract][Full Text] [Related]
17. Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.
Naguib A; Mitrou PN; Gay LJ; Cooke JC; Luben RN; Ball RY; McTaggart A; Arends MJ; Rodwell SA
BMC Cancer; 2010 Mar; 10():99. PubMed ID: 20233436
[TBL] [Abstract][Full Text] [Related]
18. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
19. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
20. BRAF, K-ras and BAT26 mutations in colorectal polyps and stool.
Jin YM; Li BJ; Qu B; Du YJ
World J Gastroenterol; 2006 Aug; 12(32):5148-52. PubMed ID: 16937524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
